Form 4 for BG Bunge Global
Accepted 2025-11-25 00:00:00 ET · period of report 2025-11-21 · accession 0001628280-25-054056 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-25 | 2025-11-21 | BG | Dimopoulos Christos | Executive VP, Gbl Markets | S - Sale+OE | $94.37 | -25.3K | 104.5K | -19% | -$2.39M |
| D | 2025-11-25 | 2025-11-21 | BG | Dimopoulos Christos | Executive VP, Gbl Markets | M - OptEx | $50.07 | +5,300 | 129.8K | +4% | +$265.4K |
| D | 2025-11-25 | 2025-11-21 | BG | Dimopoulos Christos | Executive VP, Gbl Markets | M - OptEx | $0.00 | -5,300 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-21 | S | D | 5,300 | $94.38 | 124,536.81 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $94.30 to $94.48. The price reported reflects the weighted average sale price. The reporting person undertakes to provide to Bunge Global SA, any security holder of Bunge Global SA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. |
| 2 | Common | Common Stock | 2025-11-21 | S | D | 20,000 | $94.37 | 104,536.81 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $94.28 to $94.44. The price reported reflects the weighted average sale price. The reporting person undertakes to provide to Bunge Global SA, any security holder of Bunge Global SA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. |
| 3 | Common | Common Stock | 2025-11-21 | M | A | 5,300 | $50.07 | 129,836.81 | D | — | — | |
| 4 | Derivative | Stock Options (Right to buy) | 2025-11-21 | M | D | 5,300 | $0.00 | 0 | D | $50.07 · — to 2026-03-01 | 5,300 Common Stock | (F3) This option became exercisable in three equal annual installments beginning on March 1, 2017. |